Abstract 91P
Background
Pulmonary metastasis is the most frequently occurring distant metastases of hepatocellular carcinoma (HCC). However, the indicated mechanism of pulmonary metastasis in HCC remains unclarified. Erythroid progenitor-differentiated myeloid cells (EDMCs) were reported to mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. The role of EDMCs in the metastasis of HCC and the development of pulmonary metastasis was investigated here.
Methods
The existence of EDMCs in the circulation and spleen of HCC mouse model were validated through Flow Cytometry. EDMCs were sorted using fluorescence-activated cell sorting. CFSE stained EDMCs transfer experiment were conducted to evaluated the Pulmonary metastasis promoting role in HCC mouse model. The transwell migration and invasion experiment of hepa1-6 cells (HCC cell line) cocultured with EDMCs were performed.
Results
Mouse with Pulmonary metastasis of HCC showed higher level of EDMCs in the circulation and spleen than those without Pulmonary metastasis. CFSE EDMCs stained with 5,6- carboxyfluorescein diacetate, succinimidyl ester (CFSE) were detected in the lung of HCC mouse after infusion though caudal vein and those infused mice developed more frequency of pulmonary metastasis than those without EDMCs infusion. IN the coculture experiment EDMCs promoted the migration and invasion of hepa1-6 cells.
Conclusions
EDMCs existed in the circulation of HCC mouse model. EDMCs could migrated from the circulation to the lung of HCC mice. EDMCs could facilitate migration and invasion of hepa1-6 cells migrate and invade. Thus, EDMCs can promote Pulmonary metastasis in Hepatocellular Carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wei-hang Zhu.
Funding
National Natural Science Foundation of China (81972677, 82103331), Guangdong Basic and Applied Basic Research Foundation (No. 2021A1515011022, 2022A1515010547).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09
36P - Molecular assessment of clinical antitumour therapeutics utilising established pancreatic ductal adenocarcinoma patient-derived models
Presenter: Young-Ah Suh
Session: Poster session 09
37P - Nischarin can be a target for stromal normalisation in pancreatic ductal adenocarcinoma
Presenter: Jelena Grahovac
Session: Poster session 09
38P - Effects of antiemetics on zolbetuximab-induced gastric injury and emesis frequency in ferrets
Presenter: Jane Weng
Session: Poster session 09
39P - Casein kinase 2 modulates epithelial–mesenchymal transition through helicobacter pylori CagA-dependent pathway in gastric cancer cells
Presenter: SODAM LEE
Session: Poster session 09
40P - Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2
Presenter: Irene Moreno
Session: Poster session 09
42P - Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells
Presenter: Beatriz Serambeque
Session: Poster session 09
43P - Looking for therapeutic targets on the proteome profile of endometrial cancer stem cells
Presenter: Mafalda Laranjo
Session: Poster session 09
44P - PAUF as a target for treatment of high PAUF-expressing ovarian cancer
Presenter: Junghyun Cho
Session: Poster session 09